Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL

Experts explore the evolving role of chimeric antigen receptor (CAR) T-cell therapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), with a focus on patient selection, recent data updates, and sequencing strategies.

EP. 1: CAR-T in Second-Line DLBCL: When and for Whom?

March 26th 2025

Experts discuss the use of chimeric antigen receptor T-cell (CAR T) therapies, specifically axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), in the second-line setting for patients with diffuse large B-cell lymphoma (DLBCL), focusing on patient selection and treatment frequency.

EP. 2: Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024

March 26th 2025

Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry and insights from a Matching-Adjusted Indirect Comparison (MAIC) of liso-cel vs axicabtagene ciloleucel (axi-cel) in the second-line setting, examining how these findings influence chimeric antigen receptor T-cell therapy (CAR T) selection and decision-making based on patient factors and disease characteristics.

EP. 3: CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

April 2nd 2025

Experts discuss sequencing treatments in the third-line setting or beyond for patients who have not received chimeric antigen receptor T-cell therapy (CAR T) previously, comparing bispecific antibodies, CAR T, and other agents like polatuzumab and tafasitamab, while also considering patient factors and disease characteristics when selecting among available CAR-T options (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], and tisagenlecleucel [tisa-cel]).

EP. 4: Guiding Patients Through CAR T: Key Discussion Points

April 2nd 2025

Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process

x